Gene · 9252
RPS6KA5: ribosomal protein S6 kinase A5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPS6KA5: ribosomal protein S6 kinase A5. Genes, record 9252. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9252
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O75582 | Ribosomal protein S6 kinase alpha-5 | 802 | 8 | Ensembl, GeneID, HGNC |
Source UniProt
Patents22
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2025032204 A | 2025-03-11 | 35051 | O75582 | Espacenet |
| EP 4463571 A1 | 2024-11-20 | 245 | O75582 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 35051 | O75582 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 35051 | O75582 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 74447 | O75582 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 177418 | O75582 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9808 | O75582 | Espacenet |
| JP 2020508652 A | 2020-03-26 | 35051 | O75582 | Espacenet |
| US 9878056 B2 | 2018-01-30 | 1570 | O75582 | Espacenet |
| JP 2017141230 A | 2017-08-17 | 5638 | O75582 | Espacenet |
1 to 10 of 22
See all 22 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,374
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPS6KA5 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 6 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 5 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 4 | 2025 |
| R01NS027699 | Molecular Studies of Spinocerebellar Ataxia Type 1 | 4 | 2025 |
| P01CA108671 | Myeloproliferative Neoplasms-Research Consortium | 3 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 3 | 2025 |
| P30CA044579 | University of Virginia Cancer Center Support Grant | 3 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,374Source NIH's project files
See all 1,374 nih grantsPapers1,701
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Stress- and mitosis-dependent phosphorylation of NIFK on Ser247. | J Cell Sci | 2026 | 42504587 | PubTator, text mining | PubMed |
| Neuroinflammation promotes the development of pharmacoresistant epilepsy by triggering the MSK1/CREB signaling pathway. | Sci Rep | 2026 | 42031786 | PubTator, text mining | PubMed |
| α-mangostin, a xanthone from garcinia mangostana fruit inhibits MEK1 kinase in prostate cancer. | Nat Prod Res | 2026 | 41964468 | PubTator, text mining | PubMed |
| Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications. | Signal Transduct Target Ther | 2026 | 41881983 | PubTator, text mining | PubMed |
| ERKed by too much signaling: from oncogenic driver to therapeutic vulnerability. | Cell Mol Life Sci | 2026 | 41865130 | PubTator, text mining | PubMed |
| ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression. | Cell Death Dis | 2026 | 41856969 | PubTator, text mining | PubMed |
| Brain Permeable SGK1 Inhibitors: A Promising Therapeutic Strategy for Neurodegenerative Diseases. | J Med Chem | 2026 | 41837733 | PubTator, text mining | PubMed |
| Folinic Acid Improves Healing of Diabetic Foot Ulcers. | Wound Repair Regen | 2026 | 41795141 | PubTator, text mining | PubMed |
| Exploitation of CREB signaling by HTLV-1 and BLV: A central axis in viral persistence and leukemogenesis. | Med Oncol | 2026 | 41774334 | PubTator, text mining | PubMed |
| Defining the Active Conformation of Typical Protein Kinase Domains from Substrate-Bound PDB Structures Enables Active-State AlphaFold2 Models for All 437 Human Catalytic Protein Kinases. | bioRxiv | 2026 | 41757035 | PubTator, text mining | PubMed |
1 to 10 of 1,701
See all 1,701 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9252
GET https://conductscience.org/api/genes/v1/9252/patents?page=2